المؤلفون: Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: Limited-stage small-cell lung cancer, surrogate endpoint, overall survival, progression-free survival, time to progression, chemoradiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.1007862/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/d945687fc1ba4b6ca0be33f590f5a185Test

المؤلفون: Yin Yang, Jianyang Wang, Wenqing Wang, Tao Zhang, Jingjing Zhao, Yu Wang, Yexiong Li, Luhua Wang, Nan Bi

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: limited-stage small-cell lung cancer, surrogate endpoint, overall survival, progression-free survival, time to progression, chemoradiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: PurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.MethodsLiterature searching was performed in PubMed, Embase, and The Cochrane Library up to 2021. Prediction models were firstly established using data from phase III randomized controlled trials (RCTs) and then externally validated in phase II and retrospective studies. Correlation analysis was evaluated by a weighted linear regression model at both trial and arm levels. Cross-validation was performed to assess the consistency and robustness of the established models.Results37 studies, including 15 phase III RCTs, 12 phase II studies, and 10 retrospective studies, were selected in the final analysis. In trial-level surrogacy, a very good correlation was observed between hazard ratios (HRs) of PFS/TTP and OS (R2 = 0.783, 95% CI 0.771–0.794). In arm-level surrogacy, very good correlations were also observed between 2-year (R2 = 0.823, 95% CI 0.814–0.832), 3-year (R2 = 0.843, 95% CI 0.833–0.850), 5-year (R2 = 0.852, 95% CI 0.843–0.859) PFS/TTP, and 5-year OS. An excellent correlation was observed between 4-year PFS/TTP and 5-year OS (R2 = 0.906, 95% CI 0.901–0.910). Cross-validation demonstrated reasonable overall consistency. External validation in phase II and retrospective studies showed good agreement (R2, 0.728–0.824).ConclusionsPFS/TTP was a valid surrogate endpoint for OS in patients with LS-SCLC receiving combined chemoradiotherapy. The finding provides high-level evidence to support PFS/TTP as the primary endpoint in clinical trials so as to speed up introducing novel agents to the treatment of LS-SCLC.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/e9ca2bc0bf1e47439e1d09ce7ea5f897Test

المؤلفون: Jing Qi, Jiaqi Zhang, Xingping Ge, Xin Wang, Liming Xu, Ningbo Liu, Lujun Zhao, Ping Wang

المصدر: Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: nomogram, inflammation, immunity, biomarker, limited-stage small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: BackgroundAccumulated evidence for systemic inflammation response in several solid tumors prompts a possibility of prediction of patients’ prognosis in a more accessible and valuable manner. However, the prognostic value of peripheral blood inflammatory markers in limited-stage small cell lung cancer (LS-SCLC) remains unclear. Therefore, we investigated the prognostic values of pretreatment inflammatory indexes in LS-SCLC patients.MethodsWe retrospectively identified 334 patients with LS-SCLC and collected their pretreatment serum levels of neutrophil, platelet, lymphocyte, leukocyte, hemoglobin, and albumin, then neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) were calculated. Patients were dichotomized as low-Risk or high-Risk group based on their corresponding cutoff values. Univariate and multivariate analyses were conducted with a Cox proportional hazards model. The least absolute shrinkage and selection operator (LASSO)-Cox regression analysis was performed to construct the inflammation-related prognostic scoring system named Risk for OS. Nomograms were established to provide prognostic information, allowing for more individualized prediction of survival.ResultsHigher pretreatment platelet, lymphocyte, and albumin were indicators of favorable overall survival (OS), whereas higher NLR and SII were accompanied by inferior OS. The prognosis of patients with high Risk was significantly worse than that with low Risk in both the training group and the validation group (both p < 0.001). Comparable area under the curve (AUC) values between the training group and the validation group were observed, yielding 1-, 3-, and 5-year OS rates of 67.3% vs. 69.2%, 66.8% vs. 69.5%, and 66.7% vs. 71.4%, respectively. Multivariate analyses revealed that Risk [hazard ratio (HR) = 0.551, p < 0.001] was an independent negative prognostic indicator for OS, which was further verified in the validation set. The addition of Risk to nomogram (C-index = 0.643) harbored improved predictive accuracy for OS when compared with that of clinical factors alone (C-index = 0.606); the AUC values of 1-, 3-, and 5-year OS rates were 71.7% vs. 66.4%, 73.5% vs. 66.6%, and 71.9% vs. 65.6%, respectively.ConclusionsPretreatment peripheral blood inflammatory indexes may be a noninvasive serum biomarker for poor prognosis in LS-SCLC. The addition of Risk to the nomogram model could serve as a more powerful, economical, and practical method to predict survival for patients with LS-SCLC.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2021.713014/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/6ceb84ff64884fc69f709060f360fdc9Test

المؤلفون: Qian Wu, Yiting Xiong, Shujuan Zhang, Xinling Chen, Fengming Yi, Yiping Wei, Wenxiong Zhang

المصدر: Frontiers in Oncology, Vol 9 (2020)

مصطلحات موضوعية: twice-daily, once-daily, concurrent chemoradiotherapy, limited-stage small cell lung cancer, meta-analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and once-daily (OD) CCRT, was performed to help clinicians make better decisions.Methods: Relevant randomized controlled trials (RCTs) were collected by searching the PubMed, Ovid MEDLINE, Embase, ScienceDirect, Web of Science, the Cochrane Library, Scopus and Google Scholar databases to assess antitumor effects (overall survival, OS; progression-free survival, PFS; overall response rate, ORR) and toxicity (adverse effects, AEs).Results: We screened 1499 articles and included 5 RCTs including 1421 patients. We found that BID CCRT improved OS (hazard ratio, HR = 0.88, 95% confidence interval, CI 0.78–0.99, p = 0.03), the 1-year OS rate (OSR-1y, risk ratio, RR = 1.07, 95%CI 1.01–1.13, p = 0.03), and OSR-4y (RR = 1.22, 95%CI 1.03–1.43, p = 0.02), with better trends in OSR-2y, OSR-3y, and OSR-5y, compared to OD CCRT. In addition, BID CCRT had a higher complete response (CR, RR = 1.31, 95%CI 1.01–1.70, p = 0.04) than OD CCRT. PFS (HR = 0.92, 95%CI 0.79–1.07, p = 0.29), annual PFS rate, ORR (RR = 0.99, 95%CI 0.93–1.05, p = 0.72), and AEs for all grades (RR = 1.00, 95%CI 0.98–1.01, p = 0.57), and grades 3–5 (RR = 1.02, 95%CI 0.95–1.09, p = 0.60) were similar between the two arms.Conclusions: BID CCRT appears to be better than OD CCRT for limited-stage SCLC, with better antitumor effects (OS, OSR, and CR) and similar AEs. However, the high levels of AEs in both arms should be taken as a sign of caution. More large sample and high-quality RCTs need to be conducted to confirm our conclusions.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fonc.2019.01460/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/4f516ad2d6b34b02b6794a7c23a05d18Test

المؤلفون: Jiaqi Zhang, Lujun Zhao, Ningbo Liu, Xin Wang, Liming Xu, Jing Qi, Ping Wang, Xingping Ge

المصدر: Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Multivariate analysis, Lymphocyte, Systemic inflammation, Gastroenterology, nomogram, Internal medicine, Medicine, limited-stage small cell lung cancer, RC254-282, Original Research, business.industry, Proportional hazards model, Hazard ratio, Area under the curve, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Nomogram, immunity, medicine.anatomical_structure, Oncology, inflammation, Biomarker (medicine), biomarker, medicine.symptom, business

الوصف: BackgroundAccumulated evidence for systemic inflammation response in several solid tumors prompts a possibility of prediction of patients’ prognosis in a more accessible and valuable manner. However, the prognostic value of peripheral blood inflammatory markers in limited-stage small cell lung cancer (LS-SCLC) remains unclear. Therefore, we investigated the prognostic values of pretreatment inflammatory indexes in LS-SCLC patients.MethodsWe retrospectively identified 334 patients with LS-SCLC and collected their pretreatment serum levels of neutrophil, platelet, lymphocyte, leukocyte, hemoglobin, and albumin, then neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) were calculated. Patients were dichotomized as low-Risk or high-Risk group based on their corresponding cutoff values. Univariate and multivariate analyses were conducted with a Cox proportional hazards model. The least absolute shrinkage and selection operator (LASSO)-Cox regression analysis was performed to construct the inflammation-related prognostic scoring system named Risk for OS. Nomograms were established to provide prognostic information, allowing for more individualized prediction of survival.ResultsHigher pretreatment platelet, lymphocyte, and albumin were indicators of favorable overall survival (OS), whereas higher NLR and SII were accompanied by inferior OS. The prognosis of patients with high Risk was significantly worse than that with low Risk in both the training group and the validation group (both p < 0.001). Comparable area under the curve (AUC) values between the training group and the validation group were observed, yielding 1-, 3-, and 5-year OS rates of 67.3% vs. 69.2%, 66.8% vs. 69.5%, and 66.7% vs. 71.4%, respectively. Multivariate analyses revealed that Risk [hazard ratio (HR) = 0.551, p < 0.001] was an independent negative prognostic indicator for OS, which was further verified in the validation set. The addition of Risk to nomogram (C-index = 0.643) harbored improved predictive accuracy for OS when compared with that of clinical factors alone (C-index = 0.606); the AUC values of 1-, 3-, and 5-year OS rates were 71.7% vs. 66.4%, 73.5% vs. 66.6%, and 71.9% vs. 65.6%, respectively.ConclusionsPretreatment peripheral blood inflammatory indexes may be a noninvasive serum biomarker for poor prognosis in LS-SCLC. The addition of Risk to the nomogram model could serve as a more powerful, economical, and practical method to predict survival for patients with LS-SCLC.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cddbcc6a65633d7fef85d229964a2c17Test
http://europepmc.org/articles/PMC8531548Test